Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

With BIOCON's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 1.155000
forwardPE 38.078434
debtToEquity 50.024000
earningsGrowth 0.000000
revenueGrowth 0.196000
grossMargins 0.599150
operatingMargins 0.084370
trailingEps 3.970000
forwardEps 9.920000

BIOCON's current ratio of 1.155 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that BIOCON is financially well-prepared to meet its liabilities without difficulty.
BIOCON's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that BIOCON is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

Price projections for BIOCON have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for BIOCON's growth and market performance.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have shown a buy bias for BIOCON, marking it as a favorable investment option. This could inspire investors to see BIOCON as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.